Why did BEAM's Q4 earnings outperform forecasts so dramatically?

Beam Therapeutics's Q4 earnings outperformed forecasts due to **Revenue from BEAM-101 and BEAM-302**: 1. **BEAM-101 for SCD**: Beam Therapeutics is developing BEAM-101, a one-time, non-viral base-edited autologous hematopoietic stem cell therapy for sickle cell disease (SCD). The company is currently in Phase 1/2 clinical trials for BEAM-101. The positive data from the clinical trials could have contributed to the revenue surprise. 2. **BEAM-302 for AATD**: BEAM-302 is an in vivo base editing approach for Alpha-1 Antitrypsin Deficiency (AATD), a genetic disorder that can lead to lung or liver disease. The recent positive data from the BEAM-302 clinical trial, which demonstrated a mean of 91% corrected M-AAT in circulation at Day 28 in the 60 mg cohort, could have generated excitement among investors and contributed to the revenue surprise. In summary, the positive developments in the clinical trials for BEAM-101 and BEAM-302 could have led to increased investor confidence and a surge in revenue. |code|Ticker|Name|Date|Revenue Surprise|Total Revenue|market_code| |---|---|---|---|---|---|---| |BEAM|BEAM.O|Beam Therapeutics|2024 Q1|-9560000|7410000|185| |BEAM|BEAM.O|Beam Therapeutics|2024 Q2|-1958000|1.1772E7|185| |BEAM|BEAM.O|Beam Therapeutics|2024 Q3|-250000|1.4269E7|185| |BEAM|BEAM.O|Beam Therapeutics|2024 Q4|1.4947E7|3.0067E7|185|